Statistik Asas
| CIK | 1438533 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Travere Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| August 6, 2025 |
Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports Second Quarter 2025 Financial Results U.S. net product sales of FILSPARI® (sparsentan) grew 165% year-over-year to $71.9 million in 2Q 2025; 745 new PSFs received in the quarter sNDA seeking full approval of FILSPARI for FSGS accepted for review; PDUFA target act |
|
| August 6, 2025 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 2 to License and Collaboration Agreement This Amendment No. 2 to License and Collaboration Agreement (the “Amendment”) is made and entered into as of J |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS, |
|
| June 17, 2025 |
Calculation of Filing Fee Tables S-8 Travere Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock (par value $0.0001 per share) issuable as Inducement Awards Other 72,000 $ 19.49 $ 1,403,280. |
|
| June 17, 2025 |
As filed with the Securities and Exchange Commission on June 17, 2025 As filed with the Securities and Exchange Commission on June 17, 2025 Registration No. |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2025 |
EXHIBIT 99.1 2018 Equity Incentive Plan Adopted by the Board of Directors: April 1, 2018 Approved by the Stockholders: May 9, 2018 Amended by the Board of Directors: April 1, 2019 Approved by the Stockholders: May 8, 2019 Amended by the Board of Directors: April 8, 2020 Approved by the Stockholders: May 15, 2020 Amended by the Board of Directors: April 6, 2021 Approved by the Stockholders: May 14, |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS |
|
| May 1, 2025 |
Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports First Quarter 2025 Financial Results Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to |
|
| May 1, 2025 |
Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports First Quarter 2025 Financial Results Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission F |
|
| May 1, 2025 |
Non-Employee Director Compensation Program, as amended. EXHIBIT 10.2 Non-Employee Director Compensation Program (Updated effective March 28, 2025) (“Effective Date”) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Travere Therapeutics, Inc. (“Travere”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Poli |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| February 21, 2025 |
The Company's 2025 Executive Officer Annual Bonus Plan. EXHIBIT 10.9 2025 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan Plan Objective The purpose of the Travere Therapeutics, Inc. Executive Officer Bonus Plan (the “Plan”) is to provide incentives to and reward executive officers of Travere Therapeutics, Inc. (the “Company”) (each a “Participant,” as defined below) to achieve corporate performance goals and to work together to achieve |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specif |
|
| February 21, 2025 |
EXHIBIT 19.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INSIDER TRADING POLICY Effective Date: January 21, 2025 1.Introduction 1.1During the course of your relationship with Travere Therapeutics, Inc. (“Travere” or the “C |
|
| February 21, 2025 |
List of subsidiaries of the Company. EXHIBIT 21.1 TRAVERE THERAPEUTICS, INC. LIST OF SUBSIDIARIES No. Name 1 Travere Therapeutics Pharmaceutical, Inc. 2 Travere Therapeutics Ireland Limited 3 Travere Therapeutics Switzerland GmbH 4 Kyalin Biosciences, Inc. 5 Manchester Pharmaceuticals LLC |
|
| February 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| February 20, 2025 |
EXHIBIT 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full year 2024 Net |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| January 13, 2025 |
EXHIBIT 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Provides Corporate Update and 2025 Outlook Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver m |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2024 |
TVTX / Travere Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-tvtx093024a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* TRAVERE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 14, 2024 |
TVTX / Travere Therapeutics, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-tvtx093024a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 14, 2024 |
SC 13G 1 p24-3059sc13g.htm TRAVERE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2024 |
Travere Therapeutics Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Travere Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO, November 7, 2024 – Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expect |
|
| November 8, 2024 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) Travere Therapeutics, Inc. |
|
| November 8, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281194 PROSPECTUS SUPPLEMENT (To Prospectus dated August 1, 2024) 7,812,500 Shares Common Stock We are offering 7,812,500 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “TVTX.” On November 7, 2024, the last reported sale price of our common stock on The Nasdaq Global Market |
|
| November 8, 2024 |
Exhibit 1.1 7,812,500 Shares Travere Therapeutics, Inc. UNDERWRITING AGREEMENT November 7, 2024 JEFFERIES LLC LEERINK PARTNERS LLC As representatives of the several Underwriters listed in Schedule A hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 and c/o Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Travere Therap |
|
| November 8, 2024 |
Travere Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Travere Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, November 7, 2024 – Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, shares of its common stock. All of the shares are being offered by Travere. In addition, Travere intends to grant |
|
| November 7, 2024 |
SUBJECT TO COMPLETION, DATED NOVEMBER 7, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281194 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities and we are not soliciting an offer to buy these securities in |
|
| October 31, 2024 |
Up to $100,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-281194 PROSPECTUS SUPPLEMENT (To Prospectus dated August 1, 2024) Up to $100,000,000 Common Stock We have entered into an Amended and Restated Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our common stock offered by this prospectus supplement. In accordance with the te |
|
| October 31, 2024 |
EXHIBIT 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT THIS AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT (the “Amendment”) is made and entered into as of March 20, 2018 (“Amendment Effe |
|
| October 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| October 31, 2024 |
Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports Third Quarter 2024 Financial Results FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss potential sNDA submission for |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEU |
|
| October 31, 2024 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 Travere Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effectiv |
|
| October 31, 2024 |
Exhibit 1.1 AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM October 31, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Travere Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares o |
|
| October 18, 2024 |
TVTX / Travere Therapeutics, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 TravereTherapeuticsInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TRAVERE THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 89422G107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the ru |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commi |
|
| September 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| August 1, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.8 TRAVERE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF TRAVERE THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between TRAVERE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and ex |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| August 1, 2024 |
Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports Second Quarter 2024 Financial Results Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product sales of FILSPARI totaled $ |
|
| August 1, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.9 TRAVERE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF TRAVERE THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between TRAVERE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organiz |
|
| August 1, 2024 |
As filed with the Securities and Exchange Commission on August 1, 2024 As filed with the Securities and Exchange Commission on August 1, 2024 Registration No. |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS, |
|
| August 1, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.11 TRAVERE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF TRAVERE THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between TRAVERE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organi |
|
| August 1, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Travere Therapeutics, Inc. |
|
| August 1, 2024 |
Form of Indenture, between registrant and one or more trustees to be named Exhibit 4.12 Travere Therapeutics, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 |
|
| June 14, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) TRAVERE THERAPEUTICS, INC. |
|
| June 14, 2024 |
As filed with the Securities and Exchange Commission on June 14, 2024 As filed with the Securities and Exchange Commission on June 14, 2024 Registration No. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission F |
|
| May 13, 2024 |
EXHIBIT 99.1 2018 Equity Incentive Plan Adopted by the Board of Directors: April 1, 2018 Approved by the Stockholders: May 9, 2018 Amended by the Board of Directors: April 1, 2019 Approved by the Stockholders: May 8, 2019 Amended by the Board of Directors: April 8, 2020 Approved by the Stockholders: May 15, 2020 Amended by the Board of Directors: April 6, 2021 Approved by the Stockholders: May 14, |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS |
|
| May 6, 2024 |
Non-Employee Director Compensation Program, as amended. EXHIBIT 10.1 Non-Employee Director Compensation Program (Updated effective March 25, 2024) (“Effective Date”) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Travere Therapeutics, Inc. (“Travere”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Poli |
|
| May 6, 2024 |
Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports First Quarter 2024 Financial Results FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511 new patient sta |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission F |
|
| May 1, 2024 |
TVTX / Travere Therapeutics, Inc. / Rock Springs Capital Management LP Passive Investment SC 13G 1 rocksprings-tvtx042524.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) April 25, 2024 (Date of Event Which Requires Filing of this Statement) Check th |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specif |
|
| February 20, 2024 |
Incentive Compensation Recoupment Policy EXHIBIT 97 TRAVERE THERAPEUTICS, INC. Incentive Compensation Recoupment Policy 1.Introduction The Board of Directors (the “Board”) and the Compensation Committee (the “Compensation Committee”) of the Board of Travere Therapeutics, Inc., a Delaware corporation (the “Company”), have determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation R |
|
| February 20, 2024 |
List of subsidiaries of the Company. EXHIBIT 21.1 TRAVERE THERAPEUTICS, INC. LIST OF SUBSIDIARIES No. Name 1 Travere Therapeutics Pharmaceutical, Inc. 2 Travere Therapeutics Ireland Limited 3 Travere Therapeutics Switzerland GmbH 4 Kyalin Biosciences, Inc. 5 Manchester Pharmaceuticals LLC |
|
| February 20, 2024 |
EXHIBIT 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Trademark License & Supply Agreement This Trademark License & Supply Agreement (“Agreement”) is made effective as of May 29, 2014 (the “Effective Date”) by and betw |
|
| February 20, 2024 |
EXHIBIT 10.28 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT This Third Amendment dated March 17, 2016 (the “Amendment”) to the Trademark License and Supply Agreement |
|
| February 20, 2024 |
EXHIBIT 10.32 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIFTH AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT This Fifth Amendment to Trademark License and Supply Agreement (“Fifth Amendment”), made effective Septemb |
|
| February 20, 2024 |
EXHIBIT 10.30 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT TWO TO THE THIRD AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT This Amendment Two to the Third Amendment to Trademark License and Supply Agreement d |
|
| February 20, 2024 |
Executive Officer Annual Bonus Plan. EXHIBIT 10.10 2024 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan Plan Objective The purpose of the Travere Therapeutics, Inc. Executive Officer Bonus Plan (the “Plan”) is to provide incentives to and reward executive officers of Travere Therapeutics, Inc. (the “Company”) (each a “Participant,” as defined below) to achieve corporate performance goals and to work together to achieve |
|
| February 20, 2024 |
EXHIBIT 10.29 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT ONE TO THE THIRD AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT This Amendment One dated September 12, 2016 (the “Effective Date”) to the Third Amend |
|
| February 20, 2024 |
Non-Employee Director Compensation Program, as amended EXHIBIT 10.8 Non-Employee Director Compensation Program (Updated effective March 9, 2023) (“Effective Date”) Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Travere Therapeutics, Inc. (“Travere”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Polic |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| February 15, 2024 |
EXHIBIT 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Received 459 new patient start forms (PSFs) for FILSPARI® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN |
|
| February 14, 2024 |
TVTX / Travere Therapeutics, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Travere Therapeutics Inc (Name of Issuer) Common Shares (Title of Class of Securities) 89422G107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2024 |
TVTX / Travere Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
TVTX / Travere Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
EX-99.A 2 d724312dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this [7th] day of FEBRUARY, 2024 by and between Delaware Funds by Macquarie,® Optimum Fund Trust and Macquarie ETF Trust listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectiv |
|
| February 14, 2024 |
EX-99.B 3 d724312dex99b.htm EX-99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited incorporated by reference to 13G filings made by Macquarie Group Limited on June 7, 2023. Page 13 of 13 |
|
| February 13, 2024 |
TVTX / Travere Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02104-traveretherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Travere Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 89422G107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t |
|
| February 7, 2024 |
SC 13G/A 1 p24-0418sc13ga.htm TRAVERE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Stat |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| January 8, 2024 |
EXHIBIT 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Provides Corporate Update and 2024 Outlook Received 459 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI totaled $15 million for the fourth quarter Company on track to submit sNDA to FDA in Q1 202 |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| November 7, 2023 |
Exhibit 99.1 Contact: Investors: Media: Naomi Eichenbaum Nivi Nehra Vice President, Investor Relations Vice President, Corporate Communications 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports Third Quarter 2023 Financial Results Received 430 new patient start forms for FILSPARI®(sparsentan) in the third quarter of 2023; demand and payer coverage con |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEU |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Comm |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorp |
|
| September 7, 2023 |
TRAVERE THERAPEUTICS, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS EXHIBIT 99.1 TRAVERE THERAPEUTICS, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS On August 31, 2023 (the “Closing Date”), Travere Therapeutics, Inc., (“Travere” or the “Company”) completed the sale of substantially all of the assets that are primarily related to the Company’s business of development, manufacture (including synthesis, formulation, finishing or packagin |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| August 3, 2023 |
As filed with the Securities and Exchange Commission on August 3, 2023 As filed with the Securities and Exchange Commission on August 3, 2023 Registration No. |
|
| August 3, 2023 |
Exhibit 99.1 Contact: Investors: Media: Naomi Eichenbaum Nivi Nehra Vice President, Investor Relations Vice President, Corporate Communications 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports Second Quarter 2023 Financial Results •Received 417 new patient start forms for FILSPARI™(sparsentan) in the second quarter 2023, reflecting continued strong d |
|
| August 3, 2023 |
EXHIBIT 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of January 10, 2015 (the “Effective Date”), by and between Retrophin, Inc., a De |
|
| August 3, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) TRAVERE THERAPEUTICS, INC. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS, |
|
| July 17, 2023 |
EX-10.1 Exhibit 10.1 Execution Version CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT by and between TRAVERE THERAPEUTICS, INC. and MIRUM PHARMACEUTICALS, INC. dated as of July 16, 2023 TABLE OF CONTENT |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| May 22, 2023 |
EXHIBIT 99.1 2018 Equity Incentive Plan Adopted by the Board of Directors: April 1, 2018 Approved by the Stockholders: May 9, 2018 Amended by the Board of Directors: April 1, 2019 Approved by the Stockholders: May 8, 2019 Amended by the Board of Directors: April 8, 2020 Approved by the Stockholders: May 15, 2020 Amended by the Board of Directors: April 6, 2021 Approved by the Stockholders: May 14, |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2023 |
TVTX / Travere Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* TRAVERE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) May 15, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS |
|
| May 4, 2023 |
Exhibit 99.1 Contact: Investors: Media: Naomi Eichenbaum Nivi Nehra Vice President, Investor Relations Vice President, Corporate Communications 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports First Quarter 2023 Financial Results FILSPARI™(sparsentan) granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy (IgAN) on Fe |
|
| May 4, 2023 |
Employment Agreement, effective January 1, 2022, between the Company and Jula Inrig, M.D. EXHIBIT 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is effective as January 1, 2022 (the “Effective Date”) and is entered into by and between Travere Therapeutics, Inc., a Delaware corporation (hereinafter the “Company”), and Jula Inrig, M.D. (hereinafter “Executive”). R E C I T A L S WHEREAS, the Company and Executive wish to set forth in this Agreement the terms and co |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission F |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission F |
|
| April 13, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 12, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| April 12, 2023 |
Letter from BDO USA, LLP addressed to the Securities and Exchange Commission, dated April 1 EXHIBIT 16.1 April 11, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 6, 2023, to be filed by our former client, Travere Therapeutics, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, |
|
| March 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) March 1, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| March 1, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commi |
|
| March 1, 2023 |
8,275,000 Shares of Common Stock Pre-Funded Warrants to Purchase 1,250,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259311 PROSPECTUS SUPPLEMENT (To Prospectus dated September 3, 2021) 8,275,000 Shares of Common Stock Pre-Funded Warrants to Purchase 1,250,000 Shares of Common Stock We are offering 8,275,000 shares of our common stock, and, in lieu of shares of common stock to investors that so choose, pre-funded warrants to purchase 1 |
|
| March 1, 2023 |
Travere Therapeutics Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Travere Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, February 27, 2023 – Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175,000,000 of its common stock. All of the shares are being offered by Travere. In addition, Travere i |
|
| March 1, 2023 |
$175,000,000 Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated February 28, 2023 Relating to Preliminary Prospectus Supplement Dated February 27, 2023 Registration Statement No. |
|
| March 1, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Travere Therapeutics, Inc. |
|
| March 1, 2023 |
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants EX-99.2 Exhibit 99.2 Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants SAN DIEGO, February 28, 2023 – Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of common stock to investors who so choose, pre |
|
| March 1, 2023 |
EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT TRAVERE THERAPEUTICS, INC. Warrant Shares: Date of Issuance: March [3], 2023 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitation |
|
| March 1, 2023 |
Exhibit 1.1 8,275,000 Shares Pre-Funded Warrants to Purchase 1,250,000 Shares Travere Therapeutics, Inc. UNDERWRITING AGREEMENT February 28, 2023 JEFFERIES LLC J.P. MORGAN SECURITIES LLC BOFA SECURITIES, INC. SVB SECURITIES LLC As representatives of the several Underwriters listed in Schedule A hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o J.P. Morgan Securities LLC 383 |
|
| February 27, 2023 |
SUBJECT TO COMPLETION, DATED FEBRUARY 27, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259311 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities and we are not soliciting an offer to buy these securiti |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specif |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| February 23, 2023 |
EXHIBIT 99.1 Contact: Investors: Media: Naomi Eichenbaum Nivi Nehra Vice President, Investor Relations Vice President, Corporate Communications 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosup |
|
| February 23, 2023 |
Executive Officer Annual Bonus Plan (incorporated by reference to Exhibit 10.1 EXHIBIT 10.12 2023 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan Plan Objective The purpose of the Travere Therapeutics, Inc. Executive Officer Bonus Plan (the “Plan”) is to provide incentives to and reward executive officers of Travere Therapeutics, Inc. (the “Company”) (each a “Participant,” as defined below) to achieve corporate performance goals and to work together to achieve |
|
| February 23, 2023 |
EXHIBIT 10.39 AMENDMENT NO. 1 TO LICENSE AND COLLABORATION AGREEMENT This Amendment No. 1 to License and Collaboration Agreement (the “Amendment”) is entered into as of October 5, 2022 (the “Amendment Effective Date”) by and between Travere Therapeutics Switzerland GmbH (formerly known as Orphan Technologies Limited) (“LICENSOR”) and Vifor (International) Ltd. (“LICENSEE”). LICENSOR and LICENSEE a |
|
| February 23, 2023 |
EXHIBIT 10.37 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO MASTER MANUFACTURING SUPPLY AGREEMENT This First Amendment (the “Amendment”), effective as of the November 14, 2022 (“Amendment Effective Date”), is made by and between Trav |
|
| February 23, 2023 |
List of subsidiaries of the Company. EXHIBIT 21.1 TRAVERE THERAPEUTICS, INC. LIST OF SUBSIDIARIES No. Name 1 Travere Therapeutics Pharmaceutical, Inc. 2 Travere Therapeutics Ireland Limited 3 Travere Therapeutics Switzerland GmbH 4 Travere Therapeutics US Holdings, LLC 5 Kyalin Biosciences, Inc. 6 Manchester Pharmaceuticals LLC |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| February 14, 2023 |
TVTX / Travere Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d27sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* TRAVERE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this State |
|
| February 14, 2023 |
TVTX / Travere Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
TVTX / Travere Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
TVTX / Travere Therapeutics, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d394725dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Travere Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 89422G107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 9, 2023 |
SC 13G/A 1 p23-0700sc13ga.htm TRAVERE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Stat |
|
| February 9, 2023 |
TVTX / Travere Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02070-traveretherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Travere Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 89422G107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| January 9, 2023 |
Exhibit 99.1 Contact: Naomi Eichenbaum Vice President, Investor Relations [email protected] 888-969-7879 Travere Therapeutics Provides Corporate Update and 2023 Outlook Company well-positioned for potential FDA Subpart H approval and commercial launch of sparsentan for IgA nephropathy (IgAN) in 1Q23, followed by potential EMA approval in second half of 2023 Preliminary net product sales of $201 milli |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| October 28, 2022 |
SC 13G 1 p22-2394sc13g.htm TRAVERE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) October 18, 2022 (Date of Event Which Requires Filing of This Statement) |
|
| October 27, 2022 |
Exhibit 99.1 Contact: Investors: Media: Naomi Eichenbaum Nivi Nehra Vice President, Investor Relations Vice President, Corporate Communications 888-969-7879 888-969-7879 [email protected] [email protected] Travere Therapeutics Reports Third Quarter 2022 Financial Results EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review deci |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEU |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| August 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissi |
|
| August 18, 2022 |
As filed with the Securities and Exchange Commission on August 18, 2022 As filed with the Securities and Exchange Commission on August 18, 2022 Registration No. |
|
| August 18, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) TRAVERE THERAPEUTICS, INC. |
|
| August 17, 2022 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is effective as of September 1, 2022 (the ?Effective Date?) and is entered into by and between Travere Therapeutics, Inc., a Delaware corporation (hereinafter the ?Company?), and Christopher Cline (hereinafter ?Executive?). R E C I T A L S WHEREAS, the Company and Executive wish to set forth in this Agreement the terms |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorpo |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissi |
|
| August 4, 2022 |
Travere Therapeutics Reports Second Quarter 2022 Financial Results Exhibit 99.1 Contact: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 [email protected] Travere Therapeutics Reports Second Quarter 2022 Financial Results SAN DIEGO, August 4, 2022 ? Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update. ? New Drug Application (NDA) for acce |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS, |
|
| May 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2022 |
TVTX / Travere Therapeutics, Inc. / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-tvtx050622.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) May 06, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2022 |
Exhibit 99.1 2018 Equity Incentive Plan Adopted by the Board of Directors: April 1, 2018 Approved by the Stockholders: May 9, 2018 Amended by the Board of Directors: April 1, 2019 Approved by the Stockholders: May 8, 2019 Amended by the Board of Directors: April 8, 2020 Approved by the Stockholders: May 15, 2020 Amended by the Board of Directors: April 6, 2021 Approved by the Stockholders: May 14, |
|
| May 5, 2022 |
Non-Employee Director Compensation Program, as amended. Exhibit 10.1 Non-Employee Director Compensation Program (Updated effective March 31, 2022) (?Effective Date?) Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Travere Therapeutics, Inc. (?Travere?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Poli |
|
| May 5, 2022 |
Exhibit 99.1 Contact: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 [email protected] Travere Therapeutics Reports First Quarter 2022 Financial Results Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission F |
|
| April 20, 2022 |
EXHIBIT 10.1 Travere Therapeutics, Inc. 3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 April 19, 2022 Laura Clague Re: Retirement and Transition Agreement Dear Laura: This letter agreement (the ?Agreement?) sets forth our mutual understanding regarding your planned retirement as Chief Financial Officer of Travere Therapeutics, Inc., a Delaware corporation (the ?Company?). 1.RETIREMENT. Yo |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| April 4, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 21, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| March 11, 2022 |
Exhibit 1.1 $275,000,000 2.25% Convertible Senior Notes due 2029 Travere Therapeutics, Inc. UNDERWRITING AGREEMENT March 8, 2022 JEFFERIES LLC SVB SECURITIES LLC BOFA SECURITIES, INC. EVERCORE GROUP L.L.C. As representatives of the several Underwriters listed in Schedule A hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Securities LLC 255 California Street, 12th Floor |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissio |
|
| March 11, 2022 |
Travere Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 Travere Announces Proposed Convertible Senior Notes Offering Mar 08, 2022 SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) ? Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2029 (the ?Notes?) in an underwritten offering. Travere also expects to gr |
|
| March 11, 2022 |
Travere Prices Upsized $275 Million Convertible Senior Notes Offering Exhibit 99.2 Travere Prices Upsized $275 Million Convertible Senior Notes Offering Mar 08, 2022 SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) ? Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $275 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the ?Notes?). The sale of the Notes is expected to close on March 11, 202 |
|
| March 11, 2022 |
Exhibit 4.2 TRAVERE THERAPEUTICS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee ????????????????????? SECOND SUPPLEMENTAL INDENTURE Dated as of March 11, 2022 ????????????????????? 2.25% Convertible Senior Notes due 2029 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions. 1 Section 1.02. Other Definitions. 11 Section 1.03. Rules of |
|
| March 9, 2022 |
$275,000,000 2.25% Convertible Senior Notes due 2029 Offering Price 100% Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259311 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED SEPTEMBER 3, 2021 $275,000,000 2.25% Convertible Senior Notes due 2029 Offering Price 100% We are offering $275,000,000 aggregate principal amount of our 2.25% convertible senior notes due 2029 (the ?notes?). In addition, we have granted the underwriters an option, which is exer |
|
| March 9, 2022 |
Filed pursuant to Rule 433 Registration File No. 333-259311 Relating to the Preliminary Prospectus Supplement dated March 8, 2022 (To Prospectus dated September 3, 2021) PRICING TERM SHEET March 8, 2022 Travere Therapeutics, Inc. Offering of $275,000,000 Aggregate Principal Amount of 2.25% Convertible Senior Notes due 2029 The information in this pricing term sheet supplements Travere Therapeutics |
|
| March 9, 2022 |
Filed pursuant to Rule 433 Registration File No. 333-259311 Relating to the Preliminary Prospectus Supplement dated March 8, 2022 (To Prospectus dated September 3, 2021) Explanatory Note: This Rule 433 filing supersedes the previously submitted Rule 433 filing relating to the Preliminary Prospectus Supplement dated March 8, 2022, and is being submitted solely to correct a typographical error in on |
|
| March 9, 2022 |
EX-FILING FEES 2 d275065dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Fling Fee Tables Form S-3 (Form Type) Travere Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum A |
|
| March 8, 2022 |
$250,000,000 % Convertible Senior Notes due 2029 Offering Price % Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259311 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell, nor are they soliciting an offer to buy, the notes in any jurisdiction where the offer or sale is |
|
| February 24, 2022 |
The Company's 2022 Executive Officer Annual Bonus Plan. EXHIBIT 10.14 2022 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan Plan Objective The purpose of the Travere Therapeutics, Inc. Executive Officer Bonus Plan (the ?Plan?) is to provide incentives to and reward executive officers of Travere Therapeutics, Inc. (the ?Company?) (each a ?Participant,? as defined below) to achieve corporate performance goals and to work together to achieve |
|
| February 24, 2022 |
EXHIBIT 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT TRAVERE THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. SUBLICENSE AGREEMENT THIS SUBLICENSE AGREEMENT (the ?Agreement?) is made and entered into effective as of February 16, 2012 (the ?Effective Date?) by an |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| February 24, 2022 |
Exhibit 99.1 Contact: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 [email protected] Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and comb |
|
| February 24, 2022 |
EXHIBIT 10.27 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [?***?], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT TRAVERE THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT THIS AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT (the "Amendment") is made and entered into as of September 17, 20 |
|
| February 24, 2022 |
EXHIBIT 10.40 EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT TRAVERE THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. COMMERCIAL SUPPLY AGREEMENT (RE-021) This Commercial Supply Agreement is made as of this 16th day of December 2021 (the ?Effective Dat |
|
| February 24, 2022 |
List of subsidiaries of the Company. EX Exhibit 21.1 TRAVERE THERAPEUTICS, INC. LIST OF SUBSIDIARIES No. Name 1 Travere Therapeutics Pharmaceutical, Inc. 2 Travere Therapeutics Ireland Limited 3 Travere Therapeutics Switzerland GmbH 4 Travere Therapeutics Research Ltd 5 Travere Therapeutics US Holdings, LLC 6 Kyalin Biosciences, Inc. 7 Manchester Pharmaceuticals LLC |
|
| February 24, 2022 |
EXHIBIT 4.2 DESCRIPTION OF COMMON STOCK General Our authorized capital stock consists of 200,000,000 shares of common stock, $0.0001 par value per share, and 20,000,000 shares of preferred stock, $0.0001 par value per share. All of our authorized preferred stock is undesignated, except for 1,000 Class ?A? Preferred shares, par value $0.001 per share. No Class ?A? Preferred shares are outstanding. |
|
| February 24, 2022 |
EXHIBIT 10.26 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [?***?], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT TRAVERE THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 3 TO SUBLICENSE AGREEMENT THIS AMENDMENT NO. 3 TO SUBLICENSE AGREEMENT (the "Amendment") is made and entered into as of February 27, 201 |
|
| February 24, 2022 |
EXHIBIT 10.22 1 Travere Therapeutics, Inc. Restricted Stock Unit Grant Notice (2018 Equity Incentive Plan, as amended) Travere Therapeutics, Inc. (the "Company"), pursuant to Section 6(b) of the Company?s 2018 Equity Incentive Plan, as amended (the "Plan"), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock ("Restricted Stock Units") s |
|
| February 24, 2022 |
EXHIBIT 10.21 1 Travere Therapeutics, Inc. Stock Option Grant Notice (2018 Equity Incentive Plan, as amended) Travere Therapeutics, Inc. (the ?Company?), pursuant to its 2018 Equity Incentive Plan, as amended (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company's Common Stock set forth below. This option is subject to all of the terms and conditions |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specif |
|
| February 14, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* TRAVERE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 14, 2022 |
TVTX / Travere Therapeutics, Inc. / ARMISTICE CAPITAL, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
TVTX / Travere Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 89422G 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2022 |
TVTX / Travere Therapeutics, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d234680dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Travere Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 89422G107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 14, 2022 |
TVTX / Travere Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
EX-99.1 2 d316790dex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.0001 per share, of Travere |
|
| February 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu |
|
| February 10, 2022 |
TVTX / Travere Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Travere Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 89422G107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 10, 2022 |
EX-99.1 2 d273591dex991.htm EX-99.1 Exhibit 99.1 Contact: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 [email protected] Travere Therapeutics Provides Corporate Update and 2022 Outlook Company positioned for multiple NDA and MAA submissions for accelerated approval in 2022 SAN DIEGO, January 10, 2022 – Travere Therapeutics (NASDAQ: TVTX) today ann |
|
| January 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| January 6, 2022 |
Consulting Services Agreement dated January 1, 2022, between the Company and Noah Rosenberg, M.D. EX-10.1 2 ex101nrconsultingagreement.htm EX-10.1 EXHIBIT 10.1 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (this “Agreement”) is effective January 1, 2022 (the “Effective Date”) by and between Travere Therapeutics, Inc., 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 (“Travere”) and Noah Rosenberg, M.D (“Consultant”). WHEREAS, Travere is engaged in research, developme |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2022 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissi |
|
| December 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| December 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEU |
|
| October 29, 2021 |
EX-10.1 2 ex09302021101viforagreement.htm EX-10.1 EXHIBIT 10.1 Execution Version CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. License and Collaboration Agreement dated as of September 15, 2021 by and among Orphan Technologies Limited, Tortola (British |
|
| October 28, 2021 |
Exhibit 99.1 Contact: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 [email protected] Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress Recently reported positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgA nephropathy Following pre-NDA interactions with FDA |
|
| October 28, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| October 12, 2021 |
, 2021, between the Company and Noah Rosenberg, M.D. EXHIBIT 10.1 Transition Agreement This Transition Agreement (?Agreement?) is made and entered into by and between Noah Rosenberg, M.D. (hereinafter ?Employee?), and Travere Therapeutics, Inc., a Delaware corporation (hereinafter the ?Company?). WHEREAS, Employee currently serves as Chief Medical Officer of the Company; WHEREAS, it is anticipated that Employee will remain employed as Chief Medical |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commiss |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commi |
|
| September 15, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commi |
|
| September 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commi |
|
| September 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commis |
|
| September 3, 2021 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.11 TRAVERE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF TRAVERE THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between TRAVERE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organi |
|
| September 3, 2021 |
Form of Indenture, between registrant and one or more trustees to be named Exhibit 4.12 Travere Therapeutics, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certifica |
|
| September 3, 2021 |
As filed with the Securities and Exchange Commission on September 3, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 3, 2021 Registration No. |
|
| September 3, 2021 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.9 TRAVERE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF TRAVERE THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between TRAVERE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organiz |
|
| September 3, 2021 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.8 TRAVERE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF TRAVERE THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between TRAVERE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and ex |
|
| August 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commissi |
|
| August 13, 2021 |
TVTX / Travere Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 29, 2021 |
Exhibit 99.1 Contact: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 [email protected] Travere Therapeutics Reports Second Quarter 2021 Financial Results Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on trac |
|
| July 29, 2021 |
As filed with the Securities and Exchange Commission on July 29, 2021 As filed with the Securities and Exchange Commission on July 29, 2021 Registration No. |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS, |
|
| July 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| June 10, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF BYLAWS OF TRAVERE THERAPEUTICS, INC. (A DELAWARE CORPORATION) On June 9, 2021, the Board of Directors of Travere Therapeutics, Inc. approved the amendment of Article IX of the Bylaws of the corporation to read as follows: ARTICLE IX FORUM FOR ADJUDICATION OF DISPUTES 9.1 Unless the Corporation consents in writing to the selection of an alternative forum, the |
|
| May 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| May 19, 2021 |
EX-99.1 3 ex05-18x2021991.htm EX-99.1 EXHIBIT 99.1 2018 Equity Incentive Plan Adopted by the Board of Directors: April 1, 2018 Approved by the Stockholders: May 9, 2018 Amended by the Board of Directors: April 1, 2019 Approved by the Stockholders: May 8, 2019 Amended by the Board of Directors: April 8, 2020 Approved by the Stockholders: May 15, 2020 Amended by the Board of Directors: April 6, 2021 |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| May 19, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF TRAVERE THERAPEUTICS, INC. Travere Therapeutics, Inc. (the ?Company?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), hereby certifies that: FIRST: The name of the Company is Travere Therapeutics, Inc. The Company?s original Certificate of Inco |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36257 TRAVERE THERAPEUTICS |
|
| May 6, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2021 |
Exhibit 99.1 Contact: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 [email protected] Travere Therapeutics Reports First Quarter 2021 Financial Results Pivotal PROTECT Study of sparsentan in IgA nephropathy nears completion of patient enrollment; topline proteinuria data expected 3Q21 Net product sales of $47.4 million for the first quarter of 2021 |
|
| April 16, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 1, 2021 |
The Company's 2021 Executive Officer Annual Bonus Plan. EX-10.38 3 ex1038-1231202010k.htm EX-10.38 Exhibit 10.38 2021 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan Plan Objective The purpose of the Travere Therapeutics, Inc. Executive Officer Bonus Plan (the “Plan”) is to provide incentives to and reward executive officers of Travere Therapeutics, Inc. (the “Company”) (each a “Participant,” as defined below) to achieve corporate perfor |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specif |
|
| March 1, 2021 |
Exhibit 99.1 Contact: Chris Cline, CFA Senior Vice President, Investor Relations & Corporate Communications 888-969-7879 [email protected] Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results Recently reported that ongoing DUPLEX Study of sparsentan in FSGS achieved interim proteinuria endpoint Preparations underway for meetings with regulatory agencies in first half of 20 |
|
| March 1, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commission |
|
| March 1, 2021 |
EX-4.2 2 ex42-1231202010k.htm EX-4.2 EXHIBIT 4.2 DESCRIPTION OF COMMON STOCK General Our authorized capital stock consists of 100,000,000 shares of common stock, $0.0001 par value per share, and 20,000,000 shares of preferred stock, $0.0001 par value per share. All of our authorized preferred stock is undesignated, except for 1,000 Class “A” Preferred shares, par value $0.001 per share. No Class “ |
|
| March 1, 2021 |
List of subsidiaries of the Company. EX Exhibit 21.1 TRAVERE THERAPEUTICS, INC. LIST OF SUBSIDIARIES No. Name 1 Travere Therapeutics Pharmaceutical, Inc. 2 Travere Therapeutics Ireland Limited 3 Orphan Technologies Limited 4 Travere Therapeutics Research Ltd 5 Travere Therapeutics US Holdings, LLC 6 Kyalin Biosciences, Inc. 7 Manchester Pharmaceuticals LLC 8 Centurion Merger Sub, Inc. 9 Centurion Intermediate Sub, Inc. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TRAVERE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89422G107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Travere Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 89422G 107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 16, 2021 |
EX-1 2 d348616dex1.htm EX-1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERC |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Retrophin, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 761299106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): FEBRUARY 11, 2021 TRAVERE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36257 27-4842691 (State or other jurisdiction of incorporation) (Commi |
